MBRX stock forecast, quote, news & analysis
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin... Show more
Why Moleculin Biotech (MBRX) Stock Is Down -29% in the Last 30 Days
Key Takeaways
- MBRX shares have declined roughly 29% over the last 30 days, from about $11.38 in late September to about $8.10 on a split-adjusted basis.
- The main catalyst was a 1-for-20 reverse stock split, announced October 16 and effective October 20, which reduced the share count from approximately 20.9 million to about 1.05 million and pressured investor sentiment.
- Over the last three months, the stock is down roughly 82%, extending a slide that began with a deeply discounted equity offering and mixed clinical data in late July.
- Moleculin Biotech is a pre-revenue, Phase 3 clinical-stage company whose lead candidate, Annamycin, is being studied in relapsed or refractory acute myeloid leukemia.
- Funding and dilution remain central risks; the company priced a $9.3 million public offering at $0.75 per share in late July and still generates no product revenue.
- For additional data on the ticker's Price Targets, Earnings, and Forecast, explore Tickeron's dedicated pages.
- For automated trading ideas, readers can also explore Tickeron's Trending AI Robots.
Moleculin Biotech (MBRX) Company Overview and Market Position
Moleculin Biotech, Inc. (Nasdaq: MBRX) is a Phase 3 clinical-stage biopharmaceutical company headquartered in Houston, Texas. Its lead program, Annamycin (naxtarubicin), is a next-generation anthracycline designed to avoid multidrug resistance and the cardiotoxicity commonly associated with conventional anthracyclines. Annamycin is being evaluated in the pivotal MIRACLE trial (MB-108) in combination with cytarabine for relapsed or refractory acute myeloid leukemia, and is also in development for soft tissue sarcoma lung metastases. The company's earlier-stage pipeline includes the WP1066 immune/transcription modulator portfolio for brain, pancreatic, and other cancers, as well as the WP1122 antimetabolite portfolio targeting certain viruses and cancers. As a pre-revenue clinical developer, Moleculin's valuation is driven primarily by clinical milestones and its ability to fund operations.
Moleculin Biotech (MBRX) Stock Price Performance: Last 30 Days vs. Quarter
On a split-adjusted basis, MBRX closed near $11.38 in late September and traded near $8.10 in late October, a decline of roughly 29% over the past 30 days. The move was punctuated by the October 16 announcement of a 1-for-20 reverse stock split, effective October 20, which reduced outstanding shares from approximately 20.9 million to about 1.05 million. While a reverse split mechanically raises the quoted share price, the underlying trend has been firmly lower. Over the last three months, shares have fallen roughly 82%, from about $43.80 in late July to the current level, reflecting sustained selling pressure rather than a single-session shock.
What Drove MBRX Stock Price in the Last 30 Days
The dominant event of the past 30 days was the reverse stock split. Moleculin announced on October 16 that it would consolidate shares on a 1-for-20 basis effective October 20, a step typically used to lift a sub-$1 share price and support Nasdaq listing requirements. The announcement triggered a sharp selloff, with shares sliding in pre-market trading and through the following sessions as investors weighed the capital-structure move against the company's ongoing cash needs. The decline also extended a drift lower through September and early October that followed a steeply discounted equity raise and a mixed clinical readout in late July. On October 20, the company released a CEO Corner update highlighting continued progress in the MIRACLE trial, but concerns over the share structure outweighed the pipeline commentary.
What Drove MBRX Stock Performance Over the Last Quarter
MBRX's quarterly decline traces largely to July 31, when the company released updated blinded preliminary data from Part A of the Phase 2/3 MIRACLE trial and, the same day, priced a $9.3 million public offering at $0.75 per share with accompanying warrants. The deeply discounted offering, combined with blinded complete-remission figures that were lower than an earlier unblinded readout, sent shares down more than 60% in a single session. The stock stabilized and partially recovered through August and into early September, but resumed its decline as investors focused on the company's limited cash runway, the absence of product revenue, and the eventual reverse split. The net effect is a stock that has shed the bulk of its value over the past three months despite management's continued emphasis on clinical progress.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing artificial-intelligence trading bots. Tickeron offers hundreds of AI-driven trading robots that monitor thousands of tickers, but only the most relevant and consistently strong performers are featured in this section. The bots span a range of strategies, timeframes, and performance metrics, giving traders a way to compare approaches across different market conditions. For investors tracking names like Moleculin Biotech or the broader biotechnology sector, the page provides a data-driven lens on automated trading activity and momentum signals. Traders interested in algorithmic strategies can browse the Trending AI Robots section to see which bots are currently leading the rankings.
MBRX Stock Forecast Drivers: What Investors Should Watch Next
Investors are likely to focus next on the MIRACLE trial's progress. The company has indicated it expects to treat its 90th patient in September 2026 and to unblind full data between December 2026 and February 2027. Additional funding rounds, potential follow-through from the reverse split, and any regulatory or clinical updates on Annamycin could also move the stock. Because Moleculin remains pre-revenue with limited cash, its ability to finance the trial to completion is a key watch item, as are updates on the WP1066 and WP1122 programs and broader biotech-sector sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MBRX saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for MBRX moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 39 similar instances where the indicator exited the overbought zone. In 37 of the 39 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MBRX as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MBRX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MBRX's RSI Oscillator exited the oversold zone, 40 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for MBRX just turned positive on October 23, 2026. Looking at past instances where MBRX's MACD turned positive, the stock continued to rise in 35 of 40 cases over the following month. The odds of a continued upward trend are 88%.
Following a +5.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBRX advanced for three days, in 176 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
MBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. MBRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.306) is normal, around the industry mean (3.498). P/E Ratio (0.596) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry Biotechnology